Four Breakthroughs Changing Breast Cancer Care

Breast cancer care is advancing quickly across early-stage and metastatic disease. New data are extending time on therapy, refining treatment sequencing, and reducing treatment burden. Here are 4 key studies shaping care right now.

Extending First-Line Control in HER2+ Disease

Findings from DESTINY-Breast09 showed that trastuzumab deruxtecan plus pertuzumab significantly prolonged progression-free survival (PFS) in untreated HER2-positive metastatic breast cancer.¹ PFS lasted for >40 months on average, compared with about 27 months on standard therapy.

This shift suggests patients may stay on first-line treatment much longer before needing a change. For navigators, that means more conversations around managing side effects over time, supporting adherence, and helping patients understand that first-line care in HER2-positive disease may be entering a new era.

DESTINY-Breast05 Brings Forth a Stronger Option After Residual Disease

In patients with HER2-positive early breast cancer and residual disease after neoadjuvant therapy, trastuzumab deruxtecan reduced the risk of recurrence or death by more than 50% compared with trastuzumab emtansine.²

Outcomes at 3 years strongly favored the newer therapy, signaling a meaningful step forward for patients at higher risk of relapse. The message here is both hopeful and practical.

This study reinforces the importance of close adverse event monitoring, especially for lung toxicity, as this treatment moves earlier in care.

A Clearer Path for Dual-Positive Disease

The phase 3 PATINA trial tested whether adding palbociclib to maintenance anti-HER2 therapy plus endocrine therapy could improve outcomes in hormone receptor–positive, HER2-positive metastatic breast cancer.³ It did. Median PFS reached 44.3 months with palbociclib, compared with 29.1 months with standard therapy alone.

This matters because this subtype has long lived in a kind of treatment gray zone, sitting between HER2-driven and hormone-driven disease. PATINA offers a clearer path forward and gives care teams a more durable maintenance strategy to discuss after induction chemotherapy.

For navigators, it is a strong example of how combining targeted approaches can translate into more time before progression and, potentially, more stability for patients in day-to-day life.

neoCARHP Makes a Case for Doing Less, Carefully

The neoCARHP trial asked an important question in HER2-positive early breast cancer: can carboplatin be safely omitted from neoadjuvant therapy in some patients?⁴ And the answer appears to be yes.

Response rates for a taxane plus trastuzumab and pertuzumab were nearly identical to those for a carboplatin-containing regimen, with fewer side effects in the simplified regimen.

This is a meaningful de-escalation study. Not every advance comes from adding another drug; sometimes the breakthrough is learning when a simpler regimen can do the job.

These data support more nuanced conversations about treatment intensity, tolerability, and why some patients may do just as well with a less complex regimen.

References

1. Tolaney SM, Jiang Z, Zhang Q, et al. Trastuzumab deruxtecan plus pertuzumab for HER2-positive advanced breast cancer. N Engl J Med. 2026;394:551-562.
2. Loibl S, Park YH, Shao Z, et al. Trastuzumab deruxtecan in residual HER2-positive early breast cancer. N Engl J Med. 2026;394:845-857.
3. Metzger O, Mandrekar S, Goel S, et al. Palbociclib for hormone-receptor–positive, HER2-positive metastatic breast cancer. N Engl J Med. 2026;394:451-462.
4. Gao HF, Ye GL, Lin Y, et al. Neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in human epidermal growth factor receptor 2-positive breast cancer: the randomized noninferiority phase III neoCARHP Trial. J Clin Oncol. doi: 10.1200/JCO-25-0217